

YH/SE/57/2026-27
October 06, 2026

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1
G Block, Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051, India

Symbol: **YATHARTH**
ISIN: **INE0JO301016**

Dept. of Listing Operations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001, India

Scrip Code: **543950**
ISIN: **INE0JO301016**

Sub.: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations") regarding Corrigendum to the Notice of Extraordinary General Meeting of the Company dated September 22, 2026

Ref.: Intimation under Reg. 30 of SEBI Listing Regulations bearing reference YH/SE/51/2026-27

Dear Madam/Sir,

We refer to our above intimation, wherein the Company had informed about issuance of Notice of the Extraordinary General Meeting ("EGM") of the Company scheduled to be held on Thursday, October 15, 2026 at 11:00 A.M. IST through Video Conferencing / Other Audio-Visual Means ("EGM Notice").

Subsequent to the issuance of the EGM Notice and pursuant to the applications filed by the Company for obtaining in-principle approval of BSE Limited and the National Stock Exchange of India Limited ("NSE") with respect to Item No. 2 of the EGM Notice (i.e. issue of equity shares and warrants by way of a preferential issue on a private placement basis) ("Preferential Issue"), NSE has sought the Company to provide certain clarifications/ information in respect of the Preferential Issue, by way of issuing a corrigendum to the EGM Notice.

Accordingly, the attached Corrigendum is being issued in continuation of the said EGM Notice, which shall form an integral part of, and shall always be read in conjunction with, the EGM Notice together with the Explanatory Statement annexed thereto ("Corrigendum").

This Corrigendum is being sent through electronic mode to those Members whose email addresses are registered with the Company/Registrar and Transfer Agent/ Depositories.

This Corrigendum is also available on the website of the Company at <https://www.yatharthhospitals.com/uploads/investors/corrigendum-egm-notice.pdf>

Please take the above information on record.

Yours Faithfully,
For Yatharth Hospital & Trauma Care Services Limited

**RITESH
MISHRA**

Ritesh Mishra
Company Secretary & Compliance Officer
M. No. A51166
Encl: A/a

Digitally signed by Ritesh Mishra
DN: cn=Ritesh Mishra, o=Yatharth Hospital & Trauma Care Services Limited, email=Ritesh.Mishra@yatharthhospitals.com, c=IN
Date: 2026.10.06 12:00:00 +05'30'

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025

Tel: 011-49967892

Corporate Office

Sovereign Capital Gate, FC-12, Sec-16A, Noida-201301

Tel: 0120-6811236 | Email: cs@yatharthhospitals.com

Web: www.yatharthhospitals.com

Our Hospitals

- 📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308
- 📍 Sector-01, Greater Noida West, Uttar Pradesh-201306
- 📍 Sector-110, Noida, Uttar Pradesh-201304
- 📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246
- 📍 Sector-88, Faridabad, Haryana-121002
- 📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009
- 📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001
- 📍 NH19, Near Gurudwara Guru Ka Taal, Sikandra, Agra, Uttar Pradesh-282007

CORRIGENDUM TO THE NOTICE OF EXTRAORDINARY GENERAL MEETING

Corrigendum to the notice of the Extraordinary General Meeting (“EGM”) of the Company to be held on Thursday, October 15, 2026 at 11:00 a.m. IST through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”)

Yatharth Hospitals & Trauma Care Services Limited (“Company”) had issued a notice dated September 22, 2026 (“Notice”) for convening an EGM, scheduled to be held on Thursday, October 15, 2026 at 11:00 a.m. IST, through VC / OAVM. The Notice was dispatched to the Members of the Company on September 22, 2026 in compliance with the provisions of the Companies Act, 2013, read with the relevant rules made thereunder and the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India.

Pursuant to the requirements of Regulation 28(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, the Company had filed applications for obtaining the in-principle approval of BSE Limited and the National Stock Exchange of India Limited (“NSE”) for the proposed preferential issue of equity shares and warrants as detailed in Item No. 2 of the Notice together with the explanatory statement annexed thereto.

NSE vide its communication dated September 28, 2026, has asked the Company to provide certain clarifications and additional information with respect to the tenure of warrants, objects of the proposed preferential issue, use of the proceeds and the valuation mechanism for a preferential issue under the articles of association of the Company. NSE has also suggested to issue corrigendum to the Notice clarifying the same. Accordingly, in continuation to the Notice together with the explanatory statement annexed thereto this corrigendum (“Corrigendum”) is being issued and same shall be deemed to be an integral part of and should be read in conjunction with the Notice.

Pursuant to this Corrigendum, Members are hereby informed and requested to take note of the following changes in the explanatory statement to Item No. 2 as set out in the Notice:

Following Paragraphs of the Explanatory Statement to the EGM Notice dated September 22, 2026 stand replaced as under (with the relevant change *italicized* for reference):

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025

Tel: 011-49967892

Corporate Office

Sovereign Capital Gate, FC-12, Sec-16A, Noida-201301

Tel: 0120-6811236 | Email: cs@yatharthhospitals.com

Web: www.yatharthhospitals.com

Our Hospitals

📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308

📍 Sector-01, Greater Noida West, Uttar Pradesh-201306

📍 Sector-110, Noida, Uttar Pradesh-201304

📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246

📍 Sector-88, Faridabad, Haryana-121002

📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009

📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

📍 NH19, Near Gurudwara Guru Ka Taal, Sikandra, Agra, Uttar Pradesh-282007

A. Paragraph 2 of the table, on page 17 of the Notice shall stand replaced as under:

2.	Kinds of securities offered and the price at which the security is being offered	(i) Up to 1,30,26,516 (One Crore Thirty Lakhs Twenty Six Thousand Five Hundred Sixteen) fully paid-up equity shares of the Company of face value of INR 10 (Indian Rupees Ten) each (the “Subscription Shares”), at an issue price of INR 985.17 (Indian Rupees Nine Hundred Eighty Five and Seventeen Paise only) per Subscription Share, for an aggregate subscription share consideration of INR 12,83,33,32,767.72 (Indian Rupees One Thousand Two Hundred Eighty Three Crore Thirty Three Lakhs Thirty Two Thousand Seven Hundred Sixty Seven and Seventy Two Paise Only). (ii) Up to 1,89,47,664 (One Crore Eighty Nine Lakhs Forty Seven Thousand Six Hundred Sixty Four) warrants of the Company (the “Subscription Warrants”), each carrying the right to subscribe to 1 (one) fully paid-up equity share of face value of INR 10 (Indian Rupees Ten) each of the Company, at a per Subscription Warrant price of INR 985.17 (Indian Rupees Nine Hundred Eighty Five and Seventeen Paise), of which 25% is payable upfront and the balance 75% on exercise. The tenure of the Subscription Warrants shall not exceed 18 (eighteen) months from the date of their allotment, with 18 (eighteen) months being the maximum permissible tenure in compliance with Regulation 162(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”). Accordingly, the Subscription Warrants may be exercised any time prior to the 18 (eighteen) months. Further, in the event the proceeds from the issuance of Subscription Warrants is fully utilized by the Company towards the stated objects within 6 months from receipt of the proceeds, the Proposed Allottee may exercise the Subscription Warrants within 15 months from the date of allotment to ensure that the Company can utilize such proceeds towards the objects. The 15-month period does not constitute a separate or alternative tenure for the Subscription Warrants, and is intended only to indicate the period within which the Company expects the Proposed Allottee to exercise the Subscription Warrants, based on the estimated schedule for deployment of funds towards the objects of the proposed preferential issue.
----	--	---

B. Paragraph titled Objects of the Preferential Issue and Use of Proceeds, on page 13 of the Notice shall stand replaced as under:

1. The proceeds from the proposed Preferential Issue are proposed to be utilised for the expansion and development of the Company’s hospital network and infrastructure or expenditure requirements of the Company and its subsidiaries (including, by way of investment in its subsidiaries) and other general corporate purposes. Given that the

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025

Tel: 011-49967892

Corporate Office

Sovereign Capital Gate, FC-12, Sec-16A, Noida-201301

Tel: 0120-6811236 | Email: cs@yatharthhospitals.com

Web: www.yatharthhospitals.com

Our Hospitals

📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308

📍 Sector-01, Greater Noida West, Uttar Pradesh-201306

📍 Sector-110, Noida, Uttar Pradesh-201304

📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246

📍 Sector-88, Faridabad, Haryana-121002

📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009

📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

📍 NH19, Near Gurudwara Guru Ka Taal, Sikandra, Agra, Uttar Pradesh-282007

funds to be received against the Subscription Warrant conversion will be in tranches and the quantum of funds required on different dates may vary, therefore, the broad range of intended use of the funds for the above objects is set out hereinbelow:

Nature of utilization	Amount (in INR)	Tentative timeline for utilization
Expansion and development of the Company's hospital network and infrastructure or expenditure requirements of the Company and its subsidiaries (including, by way of investment in its subsidiaries)	13,12,50,00,227.58	3 years from the date of allotment of Subscription Shares and Subscription Warrants
	10,50,00,01,955.37	3 years from the date of exercise of Subscription Warrants
Other general corporate purposes	4,37,50,00,075.86	3 years from the date of allotment of Subscription Shares and Subscription Warrants
	3,50,00,00,651.79	3 years from the date of exercise of Subscription Warrants

The Company and its subsidiaries (i.e., AKS Medical & Research Centre Private Limited, Ramraja Multispeciality Hospital & Trauma Centre Private Limited, Pristine Infracon Private Limited, MGS Infotech Research and Solutions Private Limited, Sanskar Medica India Limited and Shanti Ved Institute of Medical Sciences Private Limited) are operating in the healthcare sector, where timely investment in hospitals and infrastructure is critical to support expansion, enhance medical facilities and improve patient care. In order to facilitate the growth and expansion of the Company's healthcare business and optimise capital allocation, the Company is in the process of identifying suitable targets and is engaging with investment advisors in this regard.

Any expansion by the Company will be undertaken in the form of:

- Direct acquisition of equity stake in target companies;
- Joint ventures or strategic partnerships with established players;
- Entry into medical service agreements/ O&M agreements;
- Asset purchase (including purchase of new equipment for the hospitals) or business transfer; or
- A combination of the above.

The Board of Directors shall evaluate and approve each acquisition opportunity on its own merits, considering commercial, financial, strategic, and regulatory considerations. The specific target(s), transaction structure, and deployment timelines will be communicated to the stock exchanges and shareholders in accordance with applicable SEBI disclosure norms at the appropriate time.

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025

Tel: 011-49967892

Corporate Office

Sovereign Capital Gate, FC-12, Sec-16A, Noida-201301

Tel: 0120-6811236 | Email: cs@yatharthhospitals.com

Web: www.yatharthhospitals.com

Our Hospitals

📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308

📍 Sector-01, Greater Noida West, Uttar Pradesh-201306

📍 Sector-110, Noida, Uttar Pradesh-201304

📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246

📍 Sector-88, Faridabad, Haryana-121002

📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009

📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

📍 NH19, Near Gurudwara Guru Ka Taal, Sikandra, Agra, Uttar Pradesh-282007

2. Deviation in Estimation of Objects: In terms of NSE Circular No. NSE/CML/2022/56 dated December 13, 2022 and BSE Circular No. 20221213-47 dated December 13, 2022, the proposed allocation of the proceeds of the Preferential Issue across its Objects may vary by $\pm 10\%$, as the fund requirements are based on management estimates, market conditions, business needs and other commercial and technical factors and the actual deployment of funds at each stage, and the proposed utilization schedule will depend on a number of factors such as financial, market and sectoral conditions, business performance and strategy, and other external factors, which may not be within the control of the Company and may result in modifications to the proposed schedule for utilization of the net proceeds at the discretion of the Board, subject to compliance with applicable laws.

Any deviation in estimation of the Objects, as permitted above, shall be used only towards the said Objects inter-se and shall not be utilised towards General Corporate Purposes.

The actual utilisation of the proceeds of the Preferential Issue and the timelines for such utilisation will depend on various factors, including financial, market and sectoral conditions, business performance, strategy and other external factors beyond the Company's control. Accordingly, the Board of Directors (or a committee thereof) may revise the utilisation schedule, subject to compliance with applicable laws.

3. Interim use of the proceeds: Any pending utilisation of the proceeds of the Preferential Issue for its Objects, the Company may, in accordance with applicable laws and the policies approved by the Board of Directors from time to time, invest such proceeds in money market instruments, debt market instruments (including liquid funds), deposits with scheduled commercial banks as may be permitted under applicable laws.
4. Given that the issue size exceeds INR 100 crores, in terms of Regulation 162A of the SEBI ICDR Regulations and other applicable laws, the Company has appointed CRISIL Ratings Limited ("**Monitoring Agency**") to monitor the use of proceeds of the Preferential Issue by the Company till 100% of such proceeds have been utilised. The Monitoring Agency shall submit its report to the Company in the format specified in Schedule XI of the SEBI ICDR Regulations on a quarterly basis, till 100% of the proceeds of the Preferential Issue have been utilised. The Board and the management of the Company shall provide their comments on the findings of the Monitoring Agency. The Company shall, within 45 (forty five) days from the end of each quarter, upload the report of the Monitoring Agency on its website and also submit the same to Stock Exchanges.

C. Paragraph 4 of the table on page 15 of the Notice shall stand replaced as under:

4.	Basis on which the price has been arrived at along with report of the registered valuer	The equity shares of the Company are listed on BSE Limited (" BSE ") and National Stock Exchange of India Limited (" NSE ") (together, the " Stock Exchanges "). The equity shares are frequently traded in terms of the SEBI ICDR Regulations and NSE, being the Stock Exchange with higher trading volumes for the said period, has been considered for determining the floor price in accordance with the SEBI ICDR Regulations.
----	---	--

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025

Tel: 011-49967892

Corporate Office

Sovereign Capital Gate, FC-12, Sec-16A, Noida-201301

Tel: 0120-6811236 | Email: cs@yatharthhospitals.com

Web: www.yatharthhospitals.com

Our Hospitals

📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308

📍 Sector-01, Greater Noida West, Uttar Pradesh-201306

📍 Sector-110, Noida, Uttar Pradesh-201304

📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246

📍 Sector-88, Faridabad, Haryana-121002

📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009

📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

📍 NH19, Near Gurudwara Guru Ka Taal, Sikandra, Agra, Uttar Pradesh-282007

	The price at which the proposed Preferential Issue of the Subscription Securities is being undertaken is not less than the floor price determined in terms of Regulations 164(1) and 166A of the SEBI ICDR Regulations. The said floor price is higher of the following viz: (a) INR 870.32 per equity share - the 90 trading days' volume weighted average price ("VWAP") of the equity shares quoted on NSE preceding the Relevant Date; (b) INR 984.70 per equity share - the 10 trading days' VWAP of the equity shares quoted on NSE preceding the Relevant Date; (c) INR 900.60 per equity share - the fair value of equity shares as determined by an independent registered valuer in accordance with Regulation 166A of the SEBI ICDR Regulations and as set out in the Valuation Report; or (d) the floor price determined in accordance with the provisions of the Articles of Association of the Company (if any such method is prescribed). In this regard, please note that Article 11(e)(ii) of the Articles of Association of the Company requires the Company to determine price of the shares pursuant to a valuation report of a registered valuer (if required under applicable laws) or determined in terms of applicable SEBI regulations. Accordingly, the Articles of Association of the Company do not prescribe a separate requirement for valuation, other than what is prescribed under applicable laws for a preferential issue. The pricing of the Subscription Shares and the Subscription Warrants to be allotted on preferential basis is INR 985.17 (Indian Rupees Nine Hundred Eighty Five and Seventeen Paise only), which is not lower than the floor price determined in the manner set out above. The Company has obtained a valuation report dated 17th September 2026 issued by Abhinav Agarwal, Registered Valuer, bearing Registration No. IBBI/RV/06/2019/12564, in terms of the provisions of the Act and Regulation 164 and Regulation 166A(1) of the SEBI ICDR Regulations. Further, the Company has obtained a valuation report dated 17th September 2026, issued by RS Grover and Associates, Chartered Accountants (FRN: 043012N) through its proprietor CA Radhey Shyam Grover, having membership no. 521023, in terms of the applicable rules and regulations of the Foreign Exchange Management Act, 1999. The aforesaid valuation reports are available on the website of the Company at https://www.yatharthhospitals.com/uploads/investors/pi-valuation-report-sebi-reg-2028.pdf and https://www.yatharthhospitals.com/uploads/investors/pi-valuation-report-fema-1999.pdf respectively.
--	---

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025

Tel: 011-49967892

Corporate Office

Sovereign Capital Gate, FC-12, Sec-16A, Noida-201301

Tel: 0120-6811236 | Email: cs@yatharthhospitals.com

Web: www.yatharthhospitals.com

Our Hospitals

📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308

📍 Sector-01, Greater Noida West, Uttar Pradesh-201306

📍 Sector-110, Noida, Uttar Pradesh-201304

📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246

📍 Sector-88, Faridabad, Haryana-121002

📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009

📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

📍 NH19, Near Gurudwara Guru Ka Taal, Sikandra, Agra, Uttar Pradesh-282007

D. Paragraph 3 of the table on page 17 of the Notice shall stand replaced as under:

3.	Basis or justification for the price (including premium, if any) at which the offer or invitation is being made	The issue price for the Subscription Securities have been determined in accordance with Regulations 164(1) and 166A of the SEBI ICDR Regulations and are not less than the floor price calculated thereunder. The said floor price is higher of the following viz: (a) INR 870.32 per equity share - the 90 trading days' volume weighted average price ("VWAP") of the equity shares quoted on NSE preceding the Relevant Date; (b) INR 984.70 per equity share - the 10 trading days' VWAP of the equity shares quoted on NSE preceding the Relevant Date; (c) INR 900.60 per equity share - the fair value of equity shares as determined by an independent registered valuer in accordance with Regulation 166A of the SEBI ICDR Regulations and as set out in the Valuation Report; or (d) the floor price determined in accordance with the provisions of the Articles of Association of the Company (if any such method is prescribed). In this regard, please note that Article 11(e)(ii) of the Articles of Association of the Company requires the Company to determine price of the shares pursuant to a valuation report of a registered valuer (if required under applicable laws) or determined in terms of applicable SEBI regulations. Accordingly, the Articles of Association of the Company do not prescribe a separate requirement for valuation, other than what is prescribed under applicable laws for a preferential issue. The pricing of the Subscription Shares and the Subscription Warrants to be allotted on preferential basis is INR 985.17 (Indian Rupees Nine Hundred Eighty Five and Seventeen Paise only), which is not lower than the floor price determined in the manner set out above. The Company has obtained a valuation report dated 17th September 2026 issued by Abhinav Agarwal, Registered Valuer, bearing Registration No. IBBI/RV/06/2019/12564, in terms of the provisions of the Act and Regulation 164 and Regulation 166A(1) of the SEBI ICDR Regulations. Further, the Company has obtained a valuation report dated 17th September 2026, issued by RS Grover and Associates, Chartered Accountants (FRN: 043012N) through its proprietor CA Radhey Shyam Grover, having membership no. 521023, in terms of the applicable rules and regulations of the Foreign Exchange Management Act, 1999.
----	---	---

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025

Tel: 011-49967892

Corporate Office

Sovereign Capital Gate, FC-12, Sec-16A, Noida-201301

Tel: 0120-6811236 | Email: cs@yatharthhospitals.com

Web: www.yatharthhospitals.com

Our Hospitals

📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308

📍 Sector-01, Greater Noida West, Uttar Pradesh-201306

📍 Sector-110, Noida, Uttar Pradesh-201304

📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246

📍 Sector-88, Faridabad, Haryana-121002

📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009

📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

📍 NH19, Near Gurudwara Guru Ka Taal, Sikandra, Agra, Uttar Pradesh-282007

All other contents of the Notice together with the explanatory statement thereof, save and except as modified or supplemented by the Corrigendum, shall remain unchanged. Capitalized terms used but not defined herein shall have the same meaning ascribed to them in the Notice and the explanatory statement annexed thereto.

This Corrigendum shall form an integral part of the Notice together with the explanatory statement annexed thereto, which has been circulated to the Members of the Company on September 22, 2026, and on and from the date hereof, the Notice together with the explanatory statement annexed thereto shall always be read in conjunction with this Corrigendum. Accordingly, all Members, Stock Exchanges, depositories, registrar and share transfer agent, agencies appointed for e-voting, other authorities, regulators, and all other concerned persons are requested to take note of the above changes.

Members may note that the Corrigendum has been uploaded on the website of the Company at the link: <https://www.yatharthhospitals.com/uploads/investors/corrigendum-egm-notice.pdf>

The Corrigendum can also be accessed from the websites of the Stock Exchanges, i.e. BSE at www.bseindia.com and NSE at www.nseindia.com.

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025

Tel: 011-49967892

Corporate Office

Sovereign Capital Gate, FC-12, Sec-16A, Noida-201301

Tel: 0120-6811236 | Email: cs@yatharthhospitals.com

Web: www.yatharthhospitals.com

Our Hospitals

📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308

📍 Sector-01, Greater Noida West, Uttar Pradesh-201306

📍 Sector-110, Noida, Uttar Pradesh-201304

📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246

📍 Sector-88, Faridabad, Haryana-121002

📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009

📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

📍 NH19, Near Gurudwara Guru Ka Taal, Sikandra, Agra, Uttar Pradesh-282007